The National Health Insurance Administration and the Health Commission jointly issued the "Several Measures to Support the High-Quality Development of Innovative Drugs"
Recently, the National Health Insurance Administration and the National Health Commission jointly issued the "Several Measures to Support the High-Quality Development of Innovative Drugs" (hereinafter referred to as the "Measures"), aiming to promote the high-quality development of my country's innovative drug industry and meet the people's growing medical and health needs. After the release of this policy, it quickly became a hot topic on the Internet. The following are related hot content and structured data analysis.
1. Policy background and core content
The Measures propose a number of support policies around key links such as innovative drug research and development, approval, medical insurance access, and clinical application, including:
1.Optimize the review and approval process: Accelerate the launch of innovative drugs and shorten the approval time;
2.Improve the medical insurance payment mechanism: Establish a dynamic adjustment mechanism to increase the reimbursement ratio of innovative drugs and medical insurance;
3.Strengthen clinical application support: Encourage medical institutions to give priority to the use of innovative drugs;
4.Strengthen intellectual property protection: Extend the exclusive period of innovative drugs market.
2. Analysis of hot topics across the Internet (next 10 days)
According to the data monitoring of the entire network, the following is the distribution of hot topics after the policy is released:
| Topic classification | Discussions (10,000 times) | Percentage |
|---|---|---|
| Support for innovative drug research and development | 45.6 | 32% |
| Medical insurance reimbursement optimization | 38.2 | 27% |
| Patient Benefit Analysis | 28.7 | 20% |
| Industrial investment opportunities | 18.5 | 13% |
| other | 9.0 | 8% |
3. Policy impact and industry feedback
After the release of the Measures, the pharmaceutical industry received a strong response. The following are the views of representative companies and experts:
| Institution/People | Summary of opinion |
|---|---|
| Hengrui Medicine | "The policy will significantly reduce the cost of innovative drugs research and development, and R&D investment is expected to increase by more than 20% in the next three years." |
| BeiGene | "Reform of medical insurance payment mechanism will help innovative drugs realize their commercial value quickly" |
| Experts from the Chinese Pharmaceutical Society | "Policies will promote my country's transformation from a major generic drug country to a strong innovative drug country" |
4. Benefits of typical innovative drugs
Some innovative drugs that have been launched are expected to benefit from the new policy first:
| Drug name | Indications | The estimated increase in medical insurance reimbursement |
|---|---|---|
| Carrelizumab | Various malignant tumors | 15%-20% |
| Zebutinib | Lymphoma | 10%-15% |
| Ericobu | Rheumatoid arthritis | 8%-12% |
5. Future Outlook
The implementation of the Measures is expected to have multiple impacts:
1.Industrial level: By 2025, the scale of my country's innovative drug market is expected to exceed 1 trillion yuan;
2.Patient level: The accessibility of medication for major diseases will be increased by more than 30%;
3.International competition: China's share in global innovative drug research and development is expected to increase to 15%.
The National Health Insurance Administration stated that it will regularly evaluate the effectiveness of policy implementation to ensure that the policy of high-quality development of innovative drugs is implemented. The issuance of the "Measures" marks a new stage of transformation and upgrading of my country's pharmaceutical industry and will provide strong support for the construction of a healthy China.
check the details
check the details
en
